
    
      This is a multi-center, randomized, double-blind, placebo-controlled study followed by an
      expansion cohort phase designed to investigate the safety, PK profile, and efficacy of a
      single injection of COVI-AMG in outpatient subjects with COVID-19 but are not likely to
      require hospital admission within 24 hours. Subjects will receive one of the following
      treatments: 40 mg COVI-AMG, 100 mg COVI-AMG, 200 mg COVI-AMG, or placebo. Subjects will be
      followed for 60 days after dosing.
    
  